Gilead Sciences Inc. (GILD): Growing Popularity as Defensive Stock [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
Gilead Sciences, Inc. (NASDAQ:GILD) has transitioned away from its volatile COVID-19 treatment revenue from Veklury. The core business in HIV and a growing oncology pipeline provide the firm with high-visibility, non-discretionary earnings. The defensive strength is the dominant position in the HIV market, which functions similarly to a utility because the treatments are life-sustaining and non-discretionary. Gilead's HIV portfolio generated $20.8 billion in 2025. Patients rarely switch treatments once stabilized, creating a highly predictable cash flow that is unaffected by broader economic cycles. During the Barclays Healthcare Conference in March, CFO Andrew Dickinson emphasized that Gilead faces no major loss of exclusivity until 2036. This runway provides a level of safety that is rare in the pharma sector. Yeztugo, the first twice-yearly HIV prevention therapy, is expected to hit $800 million in sales in 2026. READ MORE 10 Best Stocks to Buy According to Billionaire Paul Tudo
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- 2 Large-Cap Stocks to Consider Right Now and 1 We Turn Down [Yahoo! Finance]Yahoo! Finance
- Gilead's Arcus Pullback and Idvynso HIV Challenge Might Change The Case For Investing In GILD [Yahoo! Finance]Yahoo! Finance
- Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here's How to Position Now [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026Business Wire
- Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now? [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/10/26 - Beat
GILD
Sec Filings
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- 4/15/26 - Form 144
- GILD's page on the SEC website